Study finds PET/CT can help diagnose CUP syndrome

2014 03 06 11 26 36 325 200x200 Ecr 2014

VIENNA - FDG-PET/CT can identify a possible primary tumor in patients with carcinoma with unknown primary tumor (CUP) syndrome at a rate comparable to that found in autopsy studies, German researchers reported on Monday at ECR 2014.

In addition to spotting a possible primary tumor in 59% of cases, FDG-PET/CT visualized 52% additional tumor manifestations compared with conventional diagnostics, according to presenter Dr. Ilinca Sacarea of the Practice in Cologne Triangle. The studies also influenced therapy procedures in 32% of cases.

"FDG-PET/CT is and should be a valuable tool in the initial workup of patients with CUP syndrome," she said.

One of the top 10 cancers in Europe, CUP syndrome is metastatic cancer without a known primary tumor and represents 3% to 5% of all cancers. Only 10% to 20% of primary tumors are found in clinical studies; 75% are found postmortem. The average life expectancy for a patient with CUP syndrome is 12 months, Sacarea said.

The researchers sought to estimate the value of FDG-PET/CT for diagnosing primary tumors, for staging, and in therapy decisions in these patients. From a total PET/CT database of 2,800 patients from 2008 to 2013, the team retrospectively selected 156 FDG-PET/CT exams from 135 patients (68 men, 67 women) with CUP syndrome.

All subjects underwent conventional diagnosis (CT, MRI, scintigraphy, and panendoscopy), but follow-up was available in only approximately 50% of cases, according to Sacarea.

PET/CT scans were performed on a dedicated Gemini GXL16 PET/CT scanner (Philips Healthcare). Prescan patient preparation consisted of a sugar-free diet six hours prior to the scan; hydration with black coffee, tea, or water; and a blood glucose measurement of 70 to 170 mg/dL on the morning of the exam.

About an hour after patients received an intravenous injection of 200 to 300 MBq of F-18 FDG, a whole-body scan was performed, including approximately 10 bed positions of two minutes with low-dose CT. Late scans were performed 2.5 hours after injection, with two to six bed positions at two to 10 minutes with diagnostic contrast-enhanced CT and a small field-of-view. If necessary, head reclination and a prone breast device were utilized.

PET/CT identified a possible primary tumor in 92 (59%) of the 156 studies, including 31 head and neck tumors. The head and neck tumors were most commonly found in the nasopharynx (34.6%) and tonsils (23.1%), while the whole-body tumors were mostly in the lungs (38.8%) and the gastrointestinal tract (20.4%).

Overall sensitivity was 93% and specificity was 87%. Sensitivity and specificity for tumors in the head and neck were 90% and 85%, respectively. PET/CT also visualized 52% additional tumor manifestations compared to conventional diagnostics, Sacarea said.

Based on the PET/CT imaging results, therapy strategy or course was changed in 50 (32%) of the156 patients.

Supplemental research studies are now needed with higher patient follow-up rates, Sacarea said.

More in Conference
HRCT Fellowship
December 10, 2023December 12, 2023
Pancreas Imaging Fellowship
November 19, 2023November 21, 2023
Artificial intelligence in radiology workflow
November 14, 2023November 16, 2023
Online Pelvic Floor Imaging Fellowship
November 19, 2023November 21, 2023
Paediatric Neuroradiology Fellowship
December 17, 2023December 19, 2023
Page 1 of 125
Next Page